{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:18Z","timestamp":1786980918421,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T00:00:00Z","timestamp":1539388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T00:00:00Z","timestamp":1539388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10620-018-5321-z","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T23:56:25Z","timestamp":1539388585000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct02434133","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-6611","authenticated-orcid":false,"given":"Freddy","family":"Caldera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Ann","family":"Misch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumona","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hubers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Reichelderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Hayney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,13]]},"reference":[{"key":"5321_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"5321_CR2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","volume":"101","author":"GY Melmed","year":"2006","unstructured":"Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834\u20131840.","journal-title":"Am J Gastroenterol"},{"key":"5321_CR3","first-page":"1","volume":"62","author":"HQ McLean","year":"2013","unstructured":"McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2013;62:1\u201333.","journal-title":"Morb Mortal Wkly Rep"},{"key":"5321_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","volume":"298","author":"SW Roush","year":"2007","unstructured":"Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group a. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. JAMA. 2007;298:2155\u20132163.","journal-title":"JAMA"},{"key":"5321_CR5","first-page":"40","volume":"6","author":"AP Fiebelkorn","year":"2017","unstructured":"Fiebelkorn AP, Redd SB, Gasta\u00f1aduy PA, et al. A comparison of post-elimination measles epidemiology in the United States, 2009\u20132014 versus 2001\u20132008. J Pediatr Infect Dis Soc. 2017;6:40\u201348.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"5321_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1086\/528993","volume":"197","author":"I Davidkin","year":"2008","unstructured":"Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197:950\u2013956.","journal-title":"J Infect Dis"},{"key":"5321_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.vaccine.2017.12.075","volume":"36","author":"EE Seagle","year":"2018","unstructured":"Seagle EE, Bednarczyk RA, Hill T, et al. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine. 2018;36:818\u2013826.","journal-title":"Vaccine"},{"key":"5321_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.vaccine.2017.12.002","volume":"36","author":"HF Gidding","year":"2018","unstructured":"Gidding HF, Quinn HE, Hueston L, Dwyer DE, McIntyre PB. Declining measles antibodies in the era of elimination: Australia\u2019s experience. Vaccine. 2018;36:507\u2013513.","journal-title":"Vaccine"},{"key":"5321_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241\u2013258.","journal-title":"Am J Gastroenterol"},{"key":"5321_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ibd.23027","volume":"19","author":"M Naganuma","year":"2013","unstructured":"Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19:418\u2013422.","journal-title":"Inflamm Bowel Dis"},{"key":"5321_CR11","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1007\/s10620-016-4275-2","volume":"61","author":"NK Cleveland","year":"2016","unstructured":"Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61:2972\u20132976. https:\/\/doi.org\/10.1007\/s10620-016-4275-2.","journal-title":"Dig Dis Sci"},{"key":"5321_CR12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s10620-018-5043-2","volume":"63","author":"F Caldera","year":"2018","unstructured":"Caldera F, Saha S, Wald A, et al. Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci. 2018;63:1532\u20131540. https:\/\/doi.org\/10.1007\/s10620-018-5043-2.","journal-title":"Dig Dis Sci"},{"key":"5321_CR13","unstructured":"Wisconsin Department of Health Services. Wisconsin Immunization Registry (WIR). https:\/\/www.dhs.wisconsin.gov\/immunization\/wir.htm. Accessed May 1, 2018."},{"key":"5321_CR14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/jcm.33.4.811-815.1995","volume":"33","author":"S Ratnam","year":"1995","unstructured":"Ratnam S, Gadag V, West R, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol. 1995;33:811\u2013815.","journal-title":"J Clin Microbiol"},{"key":"5321_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3329\/jhpn.v27i1.3320","volume":"27","author":"P Tharmaphornpilas","year":"2009","unstructured":"Tharmaphornpilas P, Yoocharean P, Rasdjarmrearnsook A-O, Theamboonlers A, Poovorawan Y. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles\/MMR immunization programme. J Health, Popul Nutr. 2009;27:80\u201386.","journal-title":"J Health, Popul Nutr"},{"key":"5321_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","volume":"162","author":"RT Chen","year":"1990","unstructured":"Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036\u20131042.","journal-title":"J Infect Dis"},{"key":"5321_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol CVI. 2010;17:1055\u20131065.","journal-title":"Clin Vaccine Immunol CVI"},{"key":"5321_CR18","first-page":"13","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:13\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5321_CR19","doi-asserted-by":"publisher","first-page":"E399","DOI":"10.1503\/cmaj.160193","volume":"188","author":"KL Schwartz","year":"2016","unstructured":"Schwartz KL, Kwong JC, Deeks SL, et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ Can Med Assoc J. 2016;188:E399\u2013E406.","journal-title":"CMAJ Can Med Assoc J"},{"key":"5321_CR20","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/377694","volume":"189","author":"AR Hinman","year":"2004","unstructured":"Hinman AR, Lynn TV, Beller M, et al. Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 Dose among high school students during an outbreak. J Infect Dis. 2004;189:S86\u2013S90.","journal-title":"J Infect Dis"},{"key":"5321_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamapediatrics.2013.4342","volume":"168","author":"MJ Papania","year":"2014","unstructured":"Papania MJ, Wallace GS, Rota PA, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western Hemisphere: the US experience. JAMA Pediatrics. 2014;168:148\u2013155.","journal-title":"JAMA Pediatrics"},{"key":"5321_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.15585\/mmwr.mm6701a7","volume":"67","author":"M Marin","year":"2018","unstructured":"Marin M, Marlow M, Moore K, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67:33\u201338.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5321_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jmv.1890410110","volume":"41","author":"DD Erdman","year":"1993","unstructured":"Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ. Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol. 1993;41:44\u201348.","journal-title":"J Med Virol"},{"key":"5321_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1097\/MIB.0000000000000045","volume":"20","author":"PSA de Silva","year":"2014","unstructured":"de Silva PSA, Fishman LN. Transition of the patient with IBD from pediatric to adult care\u2014an assessment of current evidence. Inflamm Bowel Dis. 2014;20:1458\u20131464.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-018-5321-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:08:54Z","timestamp":1628597334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-018-5321-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5321"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5321-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,13]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Caldera, Misch, Wald, and Reichelderfer and Ms. McCrone, Ms. Garmoe, Mr. Megna, and Miss Ley declare that they have no competing interests\/financial disclosures. Dr. Hayney served on the speakers\u2019 bureau for Sanofi Pasteur Vaccines and an advisory board for GlaxoSmithKline Vaccines. Dr. Saha is a consultant with UCB Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}